Biotech and pharmaceutical scientists often have more green card evidence than they think: papers from graduate and postdoc years, patents from industry work, and senior roles on programs that reach clinical or commercial stages. The EB-1A requires "sustained national or international acclaim," shown by a major international award or "at least three" of ten criteria (8 CFR 204.5(h)(3), 2025 edition), and the EB-2 national interest waiver offers a second self-petition route.
As of October 26, 2026, the USCIS Policy Manual includes several passages that fit industry science well. This guide maps them to biotech and pharma careers.
- EB-1A requires a major international award or three of ten criteria, then a final merits review.
- A patented technology that attracted significant attention or commercialization may establish major significance.
- Being funded, patented or published does not on its own prove major significance.
- A senior research position at a distinguished company can support the leading or critical role criterion.
- The NIW guidance recognizes advanced STEM degree holders, especially in critical and emerging technologies.
- A technology that benefits only one company or its clients may not show national importance; wider adoption or licensing helps.
Which EB-1A criteria fit biotech and pharma scientists?
| EB-1A criterion | Evidence that may be offered |
|---|---|
| Original contributions of major significance | Patents that were licensed or commercialized; methods adopted by others; highly cited work |
| Authorship of scholarly articles | Peer-reviewed papers in journals or recognized conference proceedings |
| Judging the work of others | Journal peer review; grant review panels |
| Leading or critical role for distinguished organizations | Leading a program or platform at a company with a documented reputation |
| High salary | Compensation compared with scientists at a similar level |
| Published material about you | Trade or major media coverage that names you and your work |
How do patents count?
Carefully. The Policy Manual warns that work being "funded, patented, or published, while potentially demonstrating the work's originality, will not necessarily establish, on its own, that the work is of major significance to the field." But it also says "evidence that the person developed a patented technology that has attracted significant attention or commercialization may establish the significance of the person's original contribution to the field" (USCIS Policy Manual, Vol. 6, Part F, Ch. 2).
So the question is what happened after the patent: licensing, a product, use by others, or recognition in the field. A list of patent numbers without that story rarely carries the criterion on its own. "If a patent remains pending, USCIS generally requires additional supporting evidence to document the originality of the person's contribution, such as detailed reference letters" (same). Our guide to patents as evidence goes deeper.
Can an industry role be a critical role?
Yes. The Policy Manual's examples of leading or critical roles include a "senior research position for a distinguished non-academic institution or company," a "principal or named investigator for a department, institution, or business that received a merit-based government award, such as an academic research or Small Business Innovation Research (SBIR) grant," and a "founder or co-founder of, or contributor of intellectual property to, a startup business that has a distinguished reputation" (USCIS Policy Manual, Vol. 6, Part F, Ch. 2). The role must be explained "in detail by the director or a principal investigator of the relevant organization or division" (same).
For judging, the manual's examples include "peer reviewer for government research funding programs," and it requires proof that the person "actually participated in the judging" (same).
How does the NIW treat biotech work?
Favorably on merit, carefully on national importance. On merit, the Policy Manual says "merit may be established without immediate or quantifiable economic impact" and that "endeavors related to research, pure science, and the furtherance of human knowledge may qualify" (USCIS Policy Manual, Vol. 6, Part F, Ch. 5).
It also gives STEM fields specific weight: "USCIS recognizes the importance of progress in STEM fields and the essential role of persons with advanced STEM degrees in fostering this progress, especially in focused critical and emerging technologies" or other STEM areas "important to U.S. competitiveness or national security" (same). Biotechnology work often fits that description, but the petition still has to show it with evidence.
The hurdle is the employer-benefit problem. The manual says "a person developing a particular technology for use or sale by a given company may not be able to establish national importance based on evidence that this technology will have benefits for the company or its clients alone." To show broader implications, a petitioner "could demonstrate, through the submission of relevant evidence, widespread interest in adoption or licensing of the technology, a novel and important manufacturing or operational process, or how the technology stands to impact the development of similar technology by other companies" (same). For a scientist working on a therapy or platform, that means framing the endeavor around its impact on patients, the field or the industry, not only the company's pipeline. Our guide to the NIW proposed endeavor explains how to frame it.
What shows you are well positioned?
The Policy Manual's examples for the second NIW prong include "patents, trademarks, or copyrights developed by the person," "documentation demonstrating a strong citation history of the person's work," "evidence that the person's work has influenced the field of endeavor," and "a plan describing how the person intends to continue the proposed work in the United States" (USCIS Policy Manual, Vol. 6, Part F, Ch. 5). Grants and government support also count. Our guide to the NIW three prongs covers each prong.
What makes letters persuasive?
Specificity and independence. For the NIW, the Policy Manual says "letters may be persuasive when they are from experts in the person's field who have first-hand knowledge of the person's achievements, describe those achievements, provide specific examples of how the person is well positioned to advance the person's endeavor, and are supported by other independent evidence" (USCIS Policy Manual, Vol. 6, Part F, Ch. 5). In biotech, the strongest letters often come from scientists outside your company who have used or built on your work, alongside a detailed letter from a program head inside it. Our guide to EB-1A recommendation letters covers structure.
Does meeting three EB-1A criteria settle it?
No. After the criteria, officers "evaluate all the evidence together when considering the petition in its entirety for the final merits determination" (USCIS Policy Manual, Vol. 6, Part F, Ch. 2). A biotech record usually passes that step when the evidence shows influence beyond your own lab or company: citations from other groups, licensing, independent coverage or invitations to review.
What about EB-1B?
For scientists whose employer will sponsor them, EB-1B for outstanding researchers is another route; our guide to EB-1B versus EB-1A for researchers compares them. Many biotech scientists file an NIW and an EB-1A or EB-1B together.
What this means for you
- List your patents and document what happened to each: licensing, products, adoption or citations.
- Ask program leaders for detailed letters about your role, within confidentiality limits.
- Keep records of journal and grant peer review, including proof you completed it.
- For an NIW, frame your endeavor around impact beyond your employer, with evidence.
- Consider filing EB-1A and NIW in parallel if your record supports both.
- Line up letter writers outside your company who have used or cited your work.
Where to start
Our free evaluation at /evaluate/ maps your record against the EB-1A and EB-2 NIW standards, and Frank, our AI assistant at /frank, finds real opportunities for the criteria you are missing. Petitions are reviewed and filed by our partner law firm, Lai & Turner.
Sources
All checked October 26, 2026.
- 8 CFR 204.5(h) (govinfo, 2025 edition). EB-1A standard and criteria.
- USCIS Policy Manual, Volume 6, Part F, Chapter 2. Patents and major significance; critical role examples; judging.
- USCIS Policy Manual, Volume 6, Part F, Chapter 5. NIW merit; STEM and critical and emerging technologies; employer-benefit limit; well-positioned evidence.
Frequently asked questions
Can an industry scientist without many publications qualify for EB-1A?
Yes, if other criteria are strong. The Policy Manual says a patented technology that attracted significant attention or commercialization may establish major significance, and a senior research position at a distinguished company can be a critical role. Peer review, high salary and published material about your work can add criteria. The final merits review then asks whether the whole record shows sustained acclaim.
Do patents count for EB-1A?
They can support original contributions of major significance, but a patent alone is not enough. The Policy Manual says being funded, patented or published does not on its own establish major significance, while evidence that a patented technology attracted significant attention or commercialization may. For pending patents, USCIS generally requires additional evidence, such as detailed reference letters, to document originality.
Is the NIW a good fit for biotech scientists?
Often. The Policy Manual recognizes the role of people with advanced STEM degrees, especially in critical and emerging technologies or areas important to US competitiveness or national security. The main hurdle is national importance: an endeavor that benefits only one company or its clients may fall short, so evidence of broader impact, such as licensing interest or effects on the wider field, matters.
Should a pharma scientist choose EB-1A, EB-1B or NIW?
It depends on the record and the employer. EB-1A is a self-petition with the highest bar. EB-1B, for outstanding researchers, needs an employer with a qualifying research division and an offer of a permanent research job. The NIW is a self-petition with a different test focused on the proposed endeavor. Many scientists file more than one.
How do confidential projects affect the evidence?
They limit what can be shown, not whether a case works. Letters from senior scientists can describe your role and results in general terms, patents and publications show the public part of the work, and regulatory or commercial milestones reported by others can show impact. The Policy Manual values detailed letters supported by other independent evidence.
Green Card Guide AI is not a law firm and this article is not legal advice. It describes evidence-building strategy in general terms; your attorney determines what belongs in your petition and how it's argued.
